Every cell in your body runs on a currency called ATP, and the factories that mint it are mitochondria. For decades, scientists knew those factories deteriorated with age. What they could not explain was the mechanism. Now, a convergence of laboratory findings published between 2021 and 2024 points to a surprisingly active process: aging mitochondria do not simply wear out in place. They shed their internal architecture, piece by piece, packaging membrane fragments into tiny bubbles that get expelled from the cell. When the cleanup crew that should catch those fragments fails, entire mitochondria get dumped overboard. What remains inside is a hollowed-out energy grid, and the consequences ripple outward into the diseases most associated with growing old.
Mitochondria are not just breaking down. They are being pushed out.
The traditional picture of mitochondrial aging was one of slow, internal decay. Newer experimental work tells a different story. In a 2023 study published in Nature Communications, researchers showed that when the protein Rab7 is deleted or lysosomal function is otherwise disrupted, cells dramatically ramp up their secretion of whole mitochondria inside large extracellular vesicles. Lysosomes are the cell’s internal recycling plants. When they go offline, mitochondria that would normally be broken down and reused are instead shoved out of the cell in membrane-wrapped packages.
That finding did not arrive in isolation. A 2021 paper in Science Advances identified a previously unknown class of particles called mitovesicles: vesicles of mitochondrial origin carrying specific mitochondrial cargo. The researchers also found that mitovesicle profiles were altered in people with Down syndrome, a condition associated with accelerated biological aging, suggesting these particles shift in composition under stress and could eventually serve as measurable markers of mitochondrial health.
Under normal conditions, cells appear to run a controlled sorting operation. A separate 2021 study in Nature Communications showed that mitochondrial components are selectively routed into extracellular vesicles through machinery involving the proteins Snx9 and OPA1. That sorting is modulated by the PINK1 and Parkin stress pathways, the same molecular players implicated in familial Parkinson’s disease. When those pathways detect damage, the sorting shifts. Instead of neatly disposing of worn parts, the cell may flood its surroundings with inflammatory mitochondrial material.
Inside the organelle, the shelves collapse
The vesicle story gains physical weight when you look at what is happening inside individual mitochondria. ATP synthase, the molecular turbine that actually produces ATP, normally sits in paired rows along tightly folded internal membranes called cristae. Structural studies have shown that with age, ATP synthase loses its dimer assembly, and those cristae collapse. Think of it as the shelving inside a warehouse buckling: the machinery falls off, and output drops.
Electron microscopy images from aged tissues confirm the picture. Mitochondria in old cells appear swollen, with sparse, disorganized cristae replacing the dense folds seen in younger counterparts. Cells from older animals also tend to harbor a higher proportion of depolarized mitochondria, reduced respiratory capacity, and disrupted cycles of fission and fusion, the processes by which mitochondria split apart and merge to maintain quality control.
These observations fit together: as cristae fragment and get exported in vesicles, the remaining mitochondrial network becomes smaller, more fragmented, and less capable of meeting the cell’s energy demands. The decline is not passive erosion. It is an active, if ultimately self-defeating, remodeling process.
At least three exit routes, and scientists are still mapping them
One of the complications in this field is that cells appear to have multiple, overlapping ways of moving mitochondrial material out. Mitochondrial-derived vesicles (MDVs) are small buds that pinch off from mitochondria and travel to lysosomes or peroxisomes. They are triggered by reactive oxygen species and protein damage, according to a synthesis of MDV biology published in 2020. Mitochondrial extracellular vesicles (mitoEVs) are larger packages that leave the cell entirely. A 2024 review cataloging mitoEVs in aging and age-related disease helped standardize the terminology but acknowledged that direct comparisons of MDV versus mitoEV release in the same cell type under controlled aging conditions have not been performed.
A third route, described in a 2024 Nature paper, adds another layer. Lysosomes can drive piecemeal removal of inner mitochondrial membrane without destroying the whole organelle. This process involves VDAC1 pores, lysosome engulfment, and the ESCRT protein machinery. It may represent a rescue mechanism, a way to prune damaged sections while keeping the rest of the mitochondrion functional. But quantitative imaging data confirming whether cristae loss precedes vesicle shedding in non-diseased mammalian models has not yet appeared in the published record.
Whether one pathway compensates when another fails, or whether all three accelerate simultaneously during aging, remains an open question as of mid-2026.
The cause-and-effect problem
Perhaps the most consequential uncertainty is whether increased vesicle release primarily protects cells or harms them. On one hand, offloading damaged mitochondrial components could prevent toxic buildup inside the cell. On the other, ejecting mitochondrial DNA and membrane fragments into the extracellular space can trigger inflammatory responses. Mitochondrial DNA is an ancient bacterial relic, and the immune system treats loose fragments of it as a danger signal.
A recent overview of mitochondrial vesicles in human pathology compiled associations between altered vesicle profiles and conditions ranging from heart failure to Alzheimer’s disease. Those correlations are suggestive, but they do not yet prove that vesicle changes are driving disease rather than reflecting damage that has already occurred.
Disentangling protective short-term responses from harmful chronic signaling is one of the field’s central challenges. Without that distinction, it is hard to know whether blocking vesicle export would slow aging or simply trap damage inside cells, potentially making things worse.
What this means for the bigger picture of aging
For readers trying to place these findings, it helps to think in three tiers of confidence. First, there is strong evidence that mitochondrial structure deteriorates with age and that cells possess multiple vesicle-based pathways to move mitochondrial material around. These are reproducible experimental results from controlled systems. Second, there is moderate evidence that these pathways become dysregulated in age-related disease, based on consistent but mostly correlative human data. Third, there is still limited evidence about whether manipulating these pathways would actually alter the pace of aging or delay disease onset in humans. Interventional studies are underway in animal models but have not yet reached clinical testing.
The practical question many people will ask, whether supplements, exercise, or drugs targeting mitochondrial health can influence these pathways, does not yet have a clear experimental answer tied specifically to vesicle shedding. Exercise is well established as a stimulus for mitochondrial biogenesis and quality control, and compounds like NAD+ precursors have shown effects on mitochondrial function in animal studies. But no published trial has measured whether these interventions reduce mitoEV or MDV release in human tissues.
The most informative experiments going forward will likely combine precise genetic or pharmacological control of vesicle pathways with long-term functional readouts in intact organisms. Tracking how targeted changes in MDV, mitoEV, or lysosome-mediated pruning affect lifespan, organ performance, and disease onset will do more to clarify causality than additional cataloging of vesicle contents alone. For now, the emerging picture of mitochondria actively shedding their inner workings stands as one of the more mechanistically grounded models of cellular energy decline, strongly supported in laboratory systems, suggestive in human tissues, and still awaiting its definitive test in the complex reality of whole-body aging.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
